Loading company
Oramed Pharmaceuticals Inc.
ORMP · Nasdaq · ·
$4.69-1.4%Sep 29 close
- 1M
- -6.8%
- 6M
- +43.0%
- 1Y
- +90.6%
- 5Y
- -78.9%
ORMP · Nasdaq · ·
$4.69-1.4%Sep 29 close
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | $78.2M | $13.3M | +488.17% |
| Profit per share | $1.84 | $0.31 | +493.55% |
| Free Cash Flow | -$202K | -$3.5M | +94.29% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Oramed Pharmaceuticals Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Oramed Pharmaceuticals Inc.’s Item 2.02 8-K filed November 17, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.